Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang, 050000, Hebei, China.
Department of Histology and Embryology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
BMC Cancer. 2018 Nov 20;18(1):1143. doi: 10.1186/s12885-018-5037-7.
Adults with relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis, especially in patients who relapsed within 6 months of complete remission 1 (CR1). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice. However, this can only be considered after complete remission 2 (CR2) is achieved. Therefore, bridging treatment is urgently needed.
In the present study, we report a relapsed adult B-cell ALL case that achieved CR2 after treatment with CD19-directed chimeric antigen receptor (CAR)-modified T cell (CAR-T) therapy. After subsequent allo-HSCT, the patient acquired 21 months of disease-free survival.
The present results confirm that both CAR-T and allo-HSCT are effective for treating refractory or relapsed B-ALL. However, a novel sequential treatment strategy with these two therapeutic methods may achieve longer disease-free survival time.
成人复发急性淋巴细胞白血病（ALL）预后较差，尤其是在完全缓解 1（CR1）后 6 个月内复发的患者。异基因造血干细胞移植（allo-HSCT）是首选治疗方法。然而，这只能在达到完全缓解 2（CR2）后考虑。因此，迫切需要桥接治疗。
本研究报告了一例复发的成人 B 细胞 ALL 病例，该病例在接受 CD19 定向嵌合抗原受体（CAR）修饰 T 细胞（CAR-T）治疗后达到 CR2。随后进行 allo-HSCT 后，患者获得了 21 个月的无病生存。
本研究结果证实，CAR-T 和 allo-HSCT 对治疗难治性或复发的 B-ALL 均有效。然而，采用这两种治疗方法的新序贯治疗策略可能会获得更长的无病生存时间。
